A supportive–expressive group intervention for women with a family history of breast cancer: results of a phase II study
✍ Scribed by Mary Jane Esplen; Brenda Toner; Jonathan Hunter; Gordon Glendon; Alexander Liede; Steve Narod; Noreen Stuckless; Kate Butler; Barb Field
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 76 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1057-9249
No coin nor oath required. For personal study only.
✦ Synopsis
Background: Evidence suggests that there are significant psychological and behavioural sequelae associated with having a family history of breast cancer (BC) which can interfere with comprehension of risk estimates.
Purpose: The purpose of this study was to develop, standardize and do preliminary testing of a group intervention designed to address the emotional impact of having a family history of BC.
Methods: This study is a single-arm pilot design with pre-and post-measures of perceived risk, psychosocial distress, knowledge and screening practices.
Results: The primary study outcome measure of risk comprehension was significantly improved by 70%, according to our predetermined criteria for success. In addition, the most important secondary measures of psychosocial functioning, such as cancer-related distress (p =0.025), depression (p= 0.05), anxiety (p= 0.005) and unresolved grief (p =0.034) were significantly improved.
Conclusion:
The results of this initial pilot study are encouraging; however, further research is required, using a randomized controlled study design to evaluate the relative contribution of this intervention to the successful modification of risk comprehension, enhanced psychological functioning, and to promote optimal screening adherence.
📜 SIMILAR VOLUMES
## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi
## BACKGROUND. Carboplatin is an analogue of cisplatin with less nonhematologic toxicity
## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo
## Background: The treatment of metastatic melanoma remains unsatisfactory despite encouraging results with biotherapy and combination chemotherapy. combining these two modalities may improve outcomes for such patients. ## Methods: Patients who were eligible for this study had metastatic melanoma